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The most effective method in treatment of inoperable cancer
is currently miniallogeneic transplantation. This type of treat-
ment focuses on reaction of ‘‘graft-versus-tumor”. According to
preliminary data, such treatment leads to long-term remission
in patients with metastatic cancer, who did not respond to
previous therapy. Anti-tumor immune response after transplant
may be extended or enhanced by additional infusion of donor
lymphocytes. Research has shown that introduction of donor
lymphocytes achieves complete remission of the tumor, even in
case of relapse after allogeneic transplantation from the same
donor, but these effects are unstable and not so long because of
rapid elimination of donor lymphocytes [1]. The main problem
is the preservation of cell transplantation viability and functional
activity of the cells in patient’s body, and protecting them
from recipient’s immune system. In recent years, most suitable
for this purpose are the three-dimensional porous biomaterials
(3D-scaffold).
Specific pore space does not allow immunity effectors
quickly destroy the cells in scaffold [2,3]. Research Institute of
medical materials and implants with shape memory at the
Tomsk State University created a porous-permeable incubators
(scaffold) of TiNi-based shape memory alloy (TiNi). The material
has unique properties: permeable porous structure by open
interconnected pores, characterized by high degree of wettabil-
ity with tissue media and nanoporous inner surface of the pore
walls, exhibits high adhesion to various cell types, so all
mentioned meet requirements of the bio-chemical and bio-
mechanical compatibility. Porous TiNi-based scaffolds allow
continually to keep the functionality cells and prolong their
action [4,5].
The purpose of this study was to investigate possibility of
modulation of antitumor response in allogeneic bone marrow
transplantation in porous-permeable incubator of TiNi.
Results: Intraperitoneal injection of allogeneic bone marrow
(BM) reduces metastasis by 30% and has easy 10%-antitumor
effect. At the same time, the implantation of bone marrow cells
on incubator of TiNi (BM + TiNi) leads to more pronounced antitu-
mor (25%) and significant antimetastatic effects (45%). Life span
of animals with tumors and implanted bone marrow cells on
incubator TiNi is increased by 60%
Since bone marrow cells do not have direct antiproliferative
effect on tumor target cells in vitro, it is assumed that one of
the mechanisms effecting the bone marrow transplantation on
neoplastic process is the stimulation of endogenous effectors of
antitumor immunity.
The study of morphological parameters immunocompetent
organs showed that administration of allogeneic bone marrow
cells can reduce thymic regression, decrease splenomegaly at ani-
mals with transplanted tumors.
Conclusion: Allogeneic transplantation of bone marrow cells
on porous incubator was shown to prolong and enhance antitu-
mor and antimetastatic action compared to injecting the cells.
This effect is directly due to the stimulation of antitumor
immunity, that is described by the study of immunity factors.
The results show perspectives of porous TiNi-based scaffolds in
complex treatment of neoplastic diseases.
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Background: Tumor cells in chronic lymphocytic leukemia
(CLL) usually have the ‘‘classic” immunophenotype CD19+,
CD5+, CD23+, SmIgdim, CD20dim, FMC7-, CD79b-/dim, CD22-/dim.
However, sometimes some deviations in antigenic profile CLL cells
are observed such as enhanced expression of CD79b, CD22, SmIg
and CD20. The most frequent cytogenetic abnormalities in CLL are
trisomy 12 and deletions of 13q14, 13q34, 6q, 11q, and 17p. It is
noted that immunophenotypic deviations in CLL often correlate
with some of these cytogenetic anomalies. The investigation of
the links between the antigens expression and caryotype of CLL
cells leads to differential diagnostics and prognosis in CLL. The goal
of the investigation is search for the links between immunopheno-
typic characteristics of CLL cells and their karyotype.
Material and methods: Bone marrow and blood cells from 35
CLL patients are investigated. Immunophenotyping was made
using flow cytometer ‘‘Cytomics F500” (Beckman Coulter) with
the use of monoclonal antibodies CD3/CD19/CD45, SmIgj
SmIgk/CD19, CD5/CD23/CD19, FMC7/CD38/CD19, CD22/CD79b/
CD19, CD10/CD20/CD19. For karyotype determination the
standard cytogenetic methods and FISH were used.
Results: The most frequent deletion in CLL patients was del(13)
(q14.3), it was sometimes observed together with (13)(q34) and
was found in18 patients (51% of all examined patients). 56%
(10/18) of patients in this group had CLL cells phenotype CD19+,
CD5+, CD23+, SmIgdim, CD20dim, FMC7-, CD79b-, CD22- and
CD38-. Weak (dim) expression of CD79b antigen (in 24–92% of
cells) was found in 39% (7/18) of patients with del(13)(q14.3),
and expression of CD38 (in 22–86% of cells) – in 17% (3/18).
The same phenotype was observed in 2 patients (6%) having
only del(13)(q34), in one patient (3%) with (13)(q34) trisomy and
in 6 patients (17%) with normal karyotype 46, XY.
Trisomy 12 was found in 14% (5/35) of explored CLL patients.
The immunophenotype of CLL cells in this group was very differ-
ent with the previous group. All patients (100%) with trisomy 12
had CLL cells with expression of CD79b (94.2% of cells), CD22
(54–94.6% of cells), CD38 (31.1–99.3% of cells). Additionally 2 of 5
patients (40%) had CLL cells with more bright (dim to mod)
CD20 expression and 1 patient (20%) had cells with bright
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expression of CD79b (in 94.2% of cells). The same phenotype was
registered in one patient with del(6q23), comprising CD78b+ (in
97.8% of cells), CD22+ (in 62.6% of cells) and CD38+ (in 32.5% of
cells). In 2 patients (6%) with del (11)(q23) expression of CD79b
(in 47.3–44.8% of cells) and CD38 (in 35.3–64.4% of cells).
Conclusion: Expression of CD79b, CD22, CD38 is the main fea-
ture of cells with recurrent genetic injuries. Immunophenotype
without expression of CD79b, CD22, CD38 in most cases differen-
tiates CLL patients with del(13)(q14.3), del (13)(q34), (13q)(34)
trisomy and with normal karyotype. Coexpression in the most
of the cells of the three antigens CD79b, CD22, CD38 and more
bright expression of CD20 proposes trisomy 12 or del(6q). Partial
expression of CD79b and CD38 may correlate with del(11)(q23).
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Breast cancer is one of the most common cancers in women.
The incidence of breast cancer in 2014 in the Republic of Mordovia
was 69.9 per 100,000 female populations. Breast cancer occurs
when excessive expression of oncoproteins switches in the case
of transformation of proto-oncogene in PRADI. In primary breast
tumors, mutations and the expression of the three oncogenes
Her2/neu, C-mys, Int-2, as well as in supressonyh genes – the
p53 gene and the retinoblastoma gene RB are the most common.
Several studies found that oncogene – C-mys was expressed in
16.8% of primary breast cancer cases and in 35% cases with sub-
sequent development of metastases. Proteins that stimulate the
phosphorylation of mitogen-activated protein kinasescan activa-
teunder the influence of growth factors. Development of breast
cancer is regulated by a complex interaction of many hormones
and growth factors. Currently, one of the leading theories of
developing breast cancer is the increased hormonal stimulation
of proliferative processes in the development of neoplasia. One
of the manifestations of hormonal imbalance in tumor during a
regular decrease in blood competitive inhibitor of the biological
effects of estrogen – progesterone, which is in correlation with
the stage of the spread of neoplasia. The role of the overproduc-
tion of estrogen in the pathogenesis of breast cancer is confirmed
by the fact that in women who underwent oophorectomy before
the age of 38 years, the risk of breast cancer development is 1.5
times less than in those who did not have such operation. Exces-
sive accumulation of lipid peroxidation products in the area of
neoplasia activates mechanisms violation of intercellular interac-
tion that caused the destruction of the lipid components of
membranes.
The study group included 112 patients treated at the State
Institution of Health of the Republic of Mordovia ‘‘National
Oncology Center”. To identify the nature of tumors, all patients
underwent immunohistochemical analysis. Androgen receptors
were found in 48% of breast cancer cases, the expression level
of androgen receptor in the tumor was much lower than the
expression level of estrogen and progesterone receptors. Low
levels of progesterone receptor expression in breast cancer cells
were combined with high levels of expression of Ki-67 antigen,
HER-2 oncoprotein in tumor cells. Patients with HER-2 (3+) and
(2+) had more frequent multiple metastases in lymph nodes com-
pared to patients with HER-2 (0) and (1+) phenotypes. Maximum
expression of HER-2 oncoprotein in tumor cells indicated high
metastatic potential and poor prognosis.
It may be concluded that the cellular and molecular mecha-
nisms of breast cancer are complex. Therefore, carcinogenesis
has a ‘‘multistep” nature and at least two or more mutations in
the cells of the same clone – parent and child are required to gen-
erate malignant tumors. Thus, the development of oncogenic
transformation does not necessarily mean the process of tumor
formation.
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Background: Identification of DNA-based biomarkers of cancer
cells is highly promising and rapidly developing direction that can
advance early detection and therapy of malignancies. DNA
adducts are felicitous markers of cancer, because their chemical
structure is significantly different from that of mutated or methy-
lated DNA, that allows to determine them with high precision
using mass spectrometry. The aim of this work is to develop the
methodology of sample preparation and its mass spectrometric
analysis. Samples were prepared from the blood plasma and from
the tumor tissue from lung cancer patients and from blood of
healthy individuals.
Materials and methods: DNA was isolated from the blood
plasma and tissue by using column method (BioSilica, Russia)
The final yield from 1 ml of blood was 100 ng. DNA samples were
subjected to acid hydrolysis (1 M HCl) at 70 C. After 3 h, the
hydrolysis was stopped by cooling on ice for 5 min and later on
adding an equivalent amount of an alkali and a phosphate buffer
solution (pH 7). To assess the extent of hydrolysis of the samples
they were analysed by electrophoresis on a 1.2% agarose gel in
Tris-acetate buffer. The samples were extracted at cartridge HF
Bond Elut-C18 100 mg, 1 ml (Agilent Technologies, USA) and
eluted in several fractions with a gradual increase of methanol
in the eluent. Stream of nitrogen was applied to dry the extract.
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